<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="90889">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02133053</url>
  </required_header>
  <id_info>
    <org_study_id>PPL-042</org_study_id>
    <nct_id>NCT02133053</nct_id>
  </id_info>
  <brief_title>Application of Ectoin Allergy Nasal Spray in Comparison to Beclomethasone Nasal Spray</brief_title>
  <official_title>Non Interventional Study of Ectoin Allergy Nasal Spray Compared to Beclomethasone Nasal Spray</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bitop AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bitop AG</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a comparative, open label, parallel group, non interventional study to further
      demonstrate the effectiveness and tolerability of Ectoin® Allergy Nasal Spray. In addition
      the effectiveness and safety shall be compared to a Beclomethasone nasal spray. The patient
      applies Ectoin® Rhinitis Nasal Spray or Beclomethasone nasal spray according to the
      instructions for use. The observation takes place over a period of 14 days. Response to
      treatment is recorded at day 7 and day 14 by the physician and in daily by the patient in a
      dairy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Change in Total Nasal Symptom Score</measure>
    <time_frame>Time Frame: day 1, day 7, day 14</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in palatal itching score</measure>
    <time_frame>Day 1, 7 and 14</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy and tolerability assessment by the patients and  by the investigator</measure>
    <time_frame>day 7 and 14</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life assessed by Rhinitis Quality of  Life Questionnaire</measure>
    <time_frame>Day1 and Day 14</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">50</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Ectoin Group</arm_group_label>
    <description>Ectoin Allergy Nasal Spray (Medical Device, drug-like)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Beclomethasone Group</arm_group_label>
    <description>Beclomethasone nasal spray</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Medical Device, drug-like</intervention_name>
    <description>Ectoin Allergy Nasal Spray</description>
    <arm_group_label>Ectoin Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beclomethasone</intervention_name>
    <description>Beclomethasone nasal spray</description>
    <arm_group_label>Beclomethasone Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Primary Care Clinic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed  allergic  rhinitis during the observational period

        Exclusion Criteria:

          -  Contra indications according to the label
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Uwe Sonnemann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HNO Praxis Elmshorn</affiliation>
  </overall_official>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 6, 2014</lastchanged_date>
  <firstreceived_date>May 2, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allergic Rhinitis</keyword>
  <keyword>Ectoine</keyword>
  <keyword>bitop</keyword>
  <keyword>Ectoin</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rhinitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Beclomethasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
